FrancophonIA/ELRC3.0 huggingface dataset:
English: Many patients with SCARs receive various mucolytic or secretolytic agents in the relevant time period before the onset of their adverse event.
Croatian: Mnogi bolesnici sa SCAR-om primaju različite mukolitike i sekretolitike tijekom relevantnog vremenskog razdoblja prije nastupanja nuspojava.
English: Efficacy issues
Croatian: Pitanje djelotvornosti
English: Some trials failed to show a significant difference between ambroxol or bromhexine and placebo and other only showed significant difference in some of the studied endpoints.
Croatian: Pojedina ispitivanja nisu uspješno utvrdila značajnu razliku između ambroksola ili bromheksina i placeba, dok su druga ispitivanja utvrdila značajnu razliku samo u nekim ispitanim završnim točkama.
English: An increase was observed in the reporting frequency of anaphylactic reactions over 2012-2014 linked to ambroxol.
Croatian: Uočena je veća učestalost prijavljivanja anafilaktičkih reakcija tijekom razdoblja od 2012. do 2014 povezanih s ambroksolom.
English: The PRAC took note of the advice of the paediatric committee (PDCO) that the use of ambroxol and bromhexine varies significantly in paediatric clinical practice across the EU.
Croatian: PRAC je uzeo u obzir savjet pedijatrijskog odbora (PDCO-a) kako primjena ambroksola i bromheksina značajno varira u pedijatrijskoj kliničkoj praksi diljem EU-a.
English: The CMDh considered the PRAC recommendation that the evidence available did not provide sufficient grounds to demonstrate a change to the established benefit-risk balance, provided the recommended amendments to sections 4.4 and 4.8 of the product information, detailed in annex III, are implemented.
Croatian: CMDh je razmotrio preporuku PRAC-a da dostupni dokazi nisu dovoljna osnova za prikazivanje promjene u utvrđenom omjeru koristi i rizika ako se primijene preporučene izmjene odjeljaka 4.4. i 4.8. o informacijama o proizvodu, podrobno opisane u Prilogu III.
English: As SCARs sometimes start with flu-like symptoms some patients might also start taking ambroxol or bromhexine to alleviate these symptoms whereas the typical skin reactions appear later and ambroxol or bromhexine might be considered as suspect drug.
Croatian: Budući da SCAR-ovi ponekad započinju simptomima sličnima gripi, pojedini bolesnici mogu također započeti terapiju ambroksolom ili bromheksinom kako bi se uklonili ti simptomi, a tipične kožne reakcije pojavljuju se kasnije, pa se ambroksol ili bromheksin mogu smatrati sumnjivim lijekovima.
English: The safety information submitted by the MAHs, from Eudravigilance and from the literature, comprises in total around 300 case reports of suspected SCARs, many of which have possible confounders.
Croatian: Informacije o sigurnoj primjeni koje je dostavio nositelj odobrenja, iz ispitivanja Eudravigilance i iz literature obuhvaćaju izvješća o ukupno otprilike 300 slučajeva sumnje na SCAR-ove, od kojih mnogi imaju moguće latentne zajedničke uzroke.
English: Based on these data it is considered that the susceptibility of all age groups (paediatric, adults and elderly) to putative hypersensitivity-related undesirable effects of ambroxol or bromhexine is likely similar.
Croatian: Na temelju tih podataka smatra se da je podložnost svih dobnih skupina (pedijatrijskih bolesnika, odraslih i starijih) mogućim neželjenim nuspojavama povezanim s preosjetljivošću na ambroksol ili bromheksin vjerojatno slična.
English: Therefore the PRAC concluded that the evidence available did not justify the introduction of further age specific restrictions in the product information.
Croatian: Stoga je PRAC zaključio kako dostupni dokazi ne opravdavaju uvođenje daljnjih ograničenja specifičnih za dobnu skupinu u informaciju o lijeku.
English: In relation to the efficacy of ambroxol- and bromhexine-containing products, the PRAC concluded that although modest positive results were reported, the evidence of efficacy of ambroxol and bromhexine suffered from a number of limitations and deficiencies.
Croatian: U vezi s djelotvornošću lijekova koji sadrže ambroksol i bromheksin, PRAC je zaključio da, iako su prijavljeni ograničeni pozitivni rezultati, dokazi o djelotvornosti ambroksola i bromheksina sadrže brojna ograničenja i nedostatke.
English: In addition, ambroxol formulations indicated in secretolytic therapy and prophylaxis or treatment of IRDS and PPC have been associated with delayed-onset hypersensitivity reactions without severe skin injury.
Croatian: Nadalje, formulacije ambroksola indicirane u sekretolitčkoj terapiji i profilaksi ili liječenju IRDS-a i PPC-a povezane su s reakcijama preosjetljivosti s odgođenim nastupanjem bez teških ozljeda kože.
English: All the available data submitted, related to the safety and the efficacy of the medicinal products were reviewed by the PRAC to assess the potential impact of the new safety concerns identified on the established benefit-risk balance of the authorised medicinal products.
Croatian: PRAC je pregledao sve dostupne podnesene podatke povezane sa sigurnošću i djelotvornošću lijekova kako bi ocijenio mogući učinak novih sigurnosnih rizika utvrđenih u pogledu ustanovljenog omjera koristi i rizika odobrenih lijekova.
English: In addition, ambroxol and bromhexine have been approved in some EU MS in airway diseases indications in fixed dose combinations with various active substances.
Croatian: Nadalje, ambroksol i bromheksin odobreni su u pojedinim državama članicama EU-a u indikacijama za bolesti dišnih putova u kombinacijama fiksnih doza s različitim djelatnim tvarima.
English: In light of the above, on 4 April 2014, the FAMHP informed the European Medicines Agency, of their decision to notify a referral procedure to ask for the PRAC's recommendation pursuant to Article 31 of Directive 2001/83/EC, on whether the balance of benefits and risks for these products is still positive in the approved indications, and whether the marketing authorisations for ambroxol- and bromhexinecontaining medicinal products should be maintained, varied, suspended or withdrawn.
Croatian: AFMPS je obavijestio Europsku agenciju za lijekove o svojoj odluci da dostavi postupak upućivanja kako bi zatražio preporuku PRAC-a sukladno članku 31. Direktive 2001/83/EZ o tome je li omjer između koristi i rizika za te proizvode i dalje pozitivan u odobrenim indikacijama te je li odobrenja za stavljanje u promet lijekova koji sadrže ambroksol i bromheksin potrebno održati, izmijeniti, privremeno oduzeti ili oduzeti.
English: The authorised indications of bromhexine, as listed in the Company Core Data Sheet of the originator, are secretolytic therapy, alteration in the production or elimination of mucus (acute and chronic sinusitis) and Sjögren's syndrome.
Croatian: Odobrene indikacije za bromheksin, koje su navedene u Listi ključnih podataka tvrtke za izvorni lijek, obuhvaćaju sekretolitčku terapiju, izmjenu u stvaranju ili eliminaciji mukusa (akutnog i kroničnog sinusitisa) i Sjögrenova sindroma.
English: When considering data in support of the safety issues, the PRAC was of the view that ambroxol- and bromhexine-containing products are associated with case reports of immediate and delayed hypersensitivity including hypersensitivity reactions, anaphylactic reactions including anaphylactic shock, angioedema, pruritus, rash and urticaria.
Croatian: Prilikom razmatranja podataka koji podupiru pitanje sigurne primjene, PRAC je bio mišljenja da su lijekovi koji sadrže ambroksol i bromheksin povezani s prijavljenim slučajevima neposredne i odgođene preosjetljivosti, uključujući reakcije preosjetljivosti, anafilaktičke reakcije, uključujući anafilaktički šok, angioedem, pruritus (svrbež), osip i urtikariju.
English: With regards to delayed hypersensitivity reactions associated with SCARs, a few cases have been assessed as certainly related to ambroxol.
Croatian: S obzirom na odgođene reakcije preosjetljivosti povezane sa SCAR-ovima, u nekoliko je slučajeva ocijenjeno da su sigurno povezani s ambroksolom.
English: This increase in reporting follows the implementation of a new pharmacovigilance regulation in China that might have influenced adverse reaction reporting and does not reflect a new safety concern.
Croatian: Ovo povećanje prijava uslijedilo je nakon provedbe novih propisa na području farmakovigilancije u Kini što je moglo utjecati na prijavljivanje nuspojava u Kini, te ne predstavlja nov razlog za zabrinutost u pogledu sigurne primjene lijeka.
English: The PRAC considered all these elements in its review of the available data on the efficacy of ambroxol- and bromhexine-containing products.
Croatian: PRAC je razmotrio sve te elemente prilikom svog pregleda dostupnih podataka o djelotvornosti lijekova koji sadrže ambroksol i bromheksin.
English: Nevertheless, modest but positive results were reported for ambroxol and bromhexine.
Croatian: Bez obzira na navedeno, prijavljeni su ograničeni, no pozitivni rezultati za lijekove ambroksol i bromheksin.
English: The PRAC however noted that the observed increase in reporting of anaphylactic reactions for ambroxol-containing products was likely an artefact resulting from the implementation of a new pharmacovigilance regulation in China and did not constitute a new safety concern.
Croatian: No PRAC je napomenuo da je uočeno povećanje u prijavljivanju anafilaktičkih reakcija za lijekove koji sadrže ambroksol vjerojatno artefakt koji je rezultat provedbe novih propisa na području farmakovigilancije u Kini te ne predstavlja novi razlog za zabrinutost u pogledu sigurne primjene.
English: Analysis of the safety information submitted by the MAH, from Eudravigilance and from the literature, demonstrates that ambroxol and bromhexine formulations in their different indications have been associated with reports of serious immediate hypersensitivity reactions.
Croatian: Analiza informacija o sigurnoj primjeni koje je dostavio nositelj odobrenja, iz ispitivanja Eudravigilance i literature pokazuje da su formulacije ambroksola i bromheksina u svojim različitim indikacijama povezane s prijavama teških neposrednih reakcija preosjetljivosti.
English: The CMDh, having considered the revised PRAC recommendation, agrees with the overall scientific conclusions by the PRAC and reached the position that the marketing authorisations for ambroxol- and bromhexine-containing medicinal products should be varied.
Croatian: Nakon što je razmotrio pregledanu preporuku PRAC-a, CMDh je suglasan s cjelokupnim znanstvenim zaključcima PRAC-a i donio je zaključak da odobrenja za stavljanje lijeka u promet za lijekove koji sadrže ambroksol i bromheksin treba izmijeniti.
English: Based on the evaluation of the individual case reports, considering the nature of these events the PRAC was of the view that there is a reasonable possibility that all ambroxol and bromhexine-containing products are associated with an increased risk of SCARs including combination products.
Croatian: Na temelju ocjene pojedinačnih prijavljenih slučajeva, uzimajući u obzir prirodu ovih slučajeva PRAC je smatrao da postoji opravdana mogućnost da su svi lijekovi koji sadrže ambroksol i bromheksin povezani s povišenim rizikom SCAR-ova, uključujući i kombinirane lijekove.
English: • The PRAC reviewed the totality of the data submitted in support of the safety and efficacy of ambroxol- and bromhexine-containing products, including submissions from the marketing authorisation holders and expert input.
Croatian: • je PRAC pregledao sve podatke dostavljene u prilog sigurne primjene i djelotvornosti lijekova koji sadrže ambroksol i bromheksin, uključujući i prijave nositelja odobrenja za stavljanje lijeka u promet i informacije stručnjaka;
English: However, these adverse reactions are already listed in the product information of most ambroxol- and bromhexinecontaining products and the analysis of the most frequently reported adverse events selected by the SMQ Hypersensitivity (broad) did not identify any new safety concerns.
Croatian: No te nuspojave već su navedene u informacijama o lijeku za većinu lijekova koji sadrže ambroksol i bromheksin, te u analizi najčešće prijavljenih nuspojava koje su odabrane postupkom SMQ za preosjetljivost (prošireni podaci) nije utvrđen nikakav nov razlog za zabrinutost u pogledu sigurne primjene lijeka.
English: Taking all of the above into consideration, the PRAC concluded that the data reviewed supported amendments of the product information to reflect the risk of severe cutaneous adverse reactions, and that further age restrictions to reflect the concerns about the benefit-risk balance of ambroxol- and bromhexine-containing products are not justified on the basis of the data available.
Croatian: Uzimajući u obzir sve prethodno navedeno, PRAC je zaključio da pregledani podaci podržavaju izmjene informacije o lijeku kako bi se prikazao rizik ozbiljnih akutnih nuspojava te da daljnja dobna ograničenja koja trebaju naglašavati zabrinutost o omjeru koristi i rizika lijekova koji sadrže ambroksol i bromheksin nisu opravdana na temelju dostupnih podataka.
English: As ambroxol is a metabolite of bromhexine and hypersensitivity reactions are not dependent on the dose of the allergenic substance absorbed, the FAMHP considered that any confirmed risk with ambroxol could also be found in bromhexine-containing medicinal products with regards to these reactions.
Croatian: Budući da je ambroksol metabolit bromheksina, a reakcije preosjetljivosti ne ovise o dozi apsorbirane alergenske tvari, AFMPS je zaključio da su, s obzirom na te reakcije, svi rizici potvrđeni kod primjene ambroksola prisutni i kod primjene lijekova koji sadrže bromheksin.
English: In addition, all studies conducted more recently submitted by the MAHs were also considered by the PRAC.
Croatian: Nadalje, PRAC je razmotrio i sve nedavno provedene studije koje je dostavio nositelj odobrenja.
English: • The PRAC was of the view that the risk of SCARs should be addressed by its inclusion in the product information accompanied by a warning in order for patients and caregivers to recognise the prodromes of SCARs and discontinue treatment immediately in the event of such signs.
Croatian: • je PRAC mišljenja kako rizik SCAR-ova treba riješiti njegovim uključivanjem u informacije o lijeku zajedno s upozorenjem kako bi bolesnici i pružatelji skrbi prepoznali prodrome SCAR-ova i prekinuli terapiju čim uoče takve znakove;
English: • The PRAC considered that ambroxol and bromhexine are associated with an increased risk of hypersensitivity reactions.
Croatian: • je PRAC zaključio kako su ambroksol i bromheksin povezani s povišenim rizikom od reakcija preosjetljivosti;
English: The PRAC considered that there was a reasonable possibility that ambroxol and bromhexine are associated with serious delayed-type hypersensitivity reactions associated with SCARs.
Croatian: PRAC je zaključio da postoji opravdana mogućnost da su ambroksol i bromheksin povezani s teškim odgođenim reakcijama preosjetljivosti povezanima sa SCAR-ovima.
English: Four cases of SCARs retrieved from Eudravigilance and 3 others from the literature have been assessed as related to ambroxol.
Croatian: Eudravigilance i tri druga slučaja iz literature ocijenjena su kao povezana s ambroksolom.
English: Hypersensitivity reactions are dose and formulation independent, therefore the possible risk of developing hypersensitivity reactions including SCARs is inherent to all ambroxol- and bromhexinecontaining products.
Croatian: Reakcije preosjetljivosti nisu ovisne o dozi i formulaciji, te je stoga mogući rizik od razvijanja reakcija preosjetljivosti, uključujući SCAR-ove, zajednički svim lijekovima koji sadrže ambroksol i bromheksin.
English: The PRAC was of the view that the possible risk of SCARs can be adequately addressed by the proposed amendments to the PI to inform caregivers and patients of the risk and allow early identification of signs of SCARs and immediate discontinuation of treatment should they occur.
Croatian: PRAC je smatrao da se mogući rizik od SCAR-ova može primjereno otkloniti predloženim izmjenama u informacijama o lijeku koje bi informirale pružatelje skrbi i bolesnike o riziku i omogućile ranu identifikaciju znakova SCAR-ova i trenutačan prekid liječenja ako oni nastupe.
English: The PRAC, as a consequence, concluded that the benefit-risk balance of of ambroxol- and bromhexinecontaining medicinal products remains favourable, subject to the above detailed amendments to the product information.
Croatian: Posljedično, PRAC je zaključio da omjer koristi i rizika za lijekove koji sadrže ambroksol i bromheksin ostaje povoljan pod uvjetom da se u informacije u lijeku unesu prethodno navedene detaljne izmjene.
English: Further to the evaluation of a Worksharing PSUR of ambroxol-containing medicinal products started in January 2012 and of follow-up submissions as well as signal detection activities, the Belgian national competent authority (FAMHP) identified an increase in reporting of hypersensitivity reactions over the years 2012-2014, reports of severe cutaneous adverse reactions (SCARs) and a benefit-risk evaluation in children below 6 years of age concluded that while there was no indication of a different safety profile, insufficient evidence of efficacy was available in secretolytic therapy in this age group, leading to a negative benefit-risk balance.
Croatian: Nakon ocjene radne skupine za podjelu posla za periodičko izvješće o neškodljivosti lijeka (PSUR) za lijekove koji sadrže ambroksol započetu u siječnju 2012. te naknadnih prijava kao i aktivnosti za otkrivanje signala, belgijsko nacionalno nadležno tijelo (AFMPS) utvrdilo je povećanje broja prijava reakcija preosjetljivosti tijekom razdoblja od 2012. do 2014., prijava teških kožnih nuspojava (engl. severe cutaneous adverse reactions - SCAR).
English: • The PRAC considered that there is a reasonable possibility of a risk of SCARs associated with ambroxol and bromhexine.
Croatian: • je PRAC zaključio kako ne postoji opravdana mogućnost rizika od SCAR-ova povezanih s ambroksolom i bromheksinom;
English: The PRAC considered that the evidence of risk of SCARs associated with ambroxol and bromhexine is weak.
Croatian: PRAC je zaključio da je rizik od SCAR-ova povezan s ambroksolom i bromheksinom slab.
English: Ambroxol- and bromhexine-containing medicines are available as over-the-counter (OTC) as well as prescription-only medicines (POM).
Croatian: Lijekovi koji sadrže ambroksol i bromheksin dostupni su kao bezreceptni lijekovi, te kao lijekovi koji se izdaju samo na liječnički recept.
English: These products are contra-indicated in different subsets of the paediatric population in the EU MS. Ambroxol and bromhexine are marketed in several formulations for oral, nasal, oromucosal, intravenous or rectal administration under various invented names.
Croatian: Ambroksol i bromheksin u prometu su u nekoliko formulacija za oralnu, nazalnu, oromukozalnu, intravenoznu ili rektalnu primjenu pod različitim izmišljenim nazivima.
English: Therefore, the PRAC recommends the variation to the terms of the marketing authorisations, for all ambroxol- and bromhexine-containing medicinal products identified in Annex I and for which the relevant sections of the Summary of Product Characteristics and Package Leaflet are set out in Annex III of the revised PRAC recommendation.
Croatian: • je PRAC zaključio da dostupni podaci nisu dostatni kako bi se opravdala nova dobna ograničenja; Stoga PRAC preporučuje izmjene uvjeta odobrenja za stavljanje u promet svih lijekova koji sadrže ambroksol i bromheksin navedenih u Prilogu I. te za koje su relevantni dijelovi sažetka opisa svojstava lijeka i uputa o lijeku navedeni u Prilogu III. pregledanoj preporuci PRAC-a.
English: Annex II Scientific conclusions
Croatian: Dodatak II
English: The authorised indications of ambroxol, as listed in the Company Core Data Sheet of the originator, are secretolytic therapy, prophylaxis and treatment of Infant Respiratory Distress Syndrome (IRDS), prophylaxis and treatment of post-operative bronchopulmonary complications (PPC) and pain relief in acute sore throat.
Croatian: Odobrene indikacije za ambroksol, koje su navedene u Listi ključnih podataka tvrtke za izvorni lijek, obuhvaćaju sekretolitičku terapiju, profilaksu i terapiju dječjeg respiratornog distres sindroma (engl.
English: If this happens, do not drive.
Croatian: Ako se to dogodi, nemojte voziti.
English: They will tell you what to do.
Croatian: Oni će vam reći što trebate učiniti.
English: Contains E223.
Croatian: Sadrži E223.
English: Allée de la Recherche 60 B-1070 Bruxelles Belgium
Croatian: Allée de la Recherche 60 B-1070 Bruxelles Belgija
English: The right dose for you will depend on your needs.
Croatian: Za Vas ispravna doza ovisit će o Vašim potrebama.
English: Augmentation may occur.
Croatian: Može se pojaviti augmentacija.
English: Do not give this medicine to children below 18 years of age because it is not known if it is safe or effective in this age group.
Croatian: Nemojte dati ovaj lijek djeci mlađoj od 18 godina jer nije poznato je li on siguran ili djelotvoran u toj dobnoj skupini.
English: Both treatments showed improvements in early morning motor function and sleep.
Croatian: Oba liječenja pokazala su poboljšanja u rano jutarnjoj motoričkoj funkciji i snu.
English: None of these patients discontinued therapy because of augmentation.
Croatian: Niti jedan od tih bolesnika nije prekinuo liječenje zbog augmentacije.
English: Interactions with other forms of hormonal contraception have not been investigated.
Croatian: Interakcije s drugim oblicima hormonalne kontracepcije nisu ispitivane.
English: The effect was maintained over a 6 months period.
Croatian: Učinak je zadržan kroz razdoblje od 6 mjeseci.
English: Leganto with food, drink and alcohol
Croatian: Leganto s hranom, pićem i alkoholom
English: Component of a multipack, can't be sold separately
Croatian: Sastavni dio višestrukog pakiranja ne može se prodavati odvojeno.
English: Do not use a double dose to make up for a forgotten dose.
Croatian: Nemojte primijeniti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
English: • Always check that the patch has not fallen off after activities such as bathing, showering or exercising.
Croatian: • Uvijek provjerite da flaster nije otpao nakon aktivnosti poput kupanja, tuširanja ili vježbanja.
English: Not known: it is not known how often these happen
Croatian: Nepoznata učestalost: nije poznato koliko se često te nuspojave javljaju
English: Leganto is applied once a day.
Croatian: Leganto se primjenjuje jednom na dan.
English: CPK levels have not been routinely measured in other populations.
Croatian: Razine CPK nisu rutinski mjerene u drugim populacijama.
English: • Please follow the instructions of the prescriber carefully.
Croatian: • Pažljivo pratite upute liječnika.
English: • unable to achieve or maintain an erection
Croatian: • nemogućnost postizanja ili održavanja erekcije
English: All differences between the active treatments and placebo were statistically significant.
Croatian: Sve razlike između aktivnog liječenja i placeba bile su statistički značajne.
English: For information on fertility studies, please see section 5.3.
Croatian: Za informacije o ispitivanjima plodnosti, molimo vidjeti dio 5.3.
English: • you may feel very sleepy or fall asleep suddenly - see ‘Driving and using machines' in section 2.
Croatian: • možete se osjećati vrlo pospano ili iznenada zaspati - pogledajte odlomak 'Upravljanje vozilima i strojevima' u dijelu 2.
English: • Talk to your doctor if you have a skin reaction that lasts longer than a few days or is severe.
Croatian: • Obratite se svom liječniku ako imate kožnu reakciju koja traje više od nekoliko dana ili je teška.
English: • strong impulse to gamble too much - even if this seriously affects you or your family
Croatian: • snažan poriv za prekomjernim kockanjem, čak i ako to ozbiljno utječe na Vas ili Vašu obitelj
English: • altered or increased sexual interest and behaviour which causes significant concern to you or others - for example, an increased sex drive
Croatian: • promijenjenu ili pojačanu spolnu želju i ponašanje, koje uzrokuje značajnu zabrinutost kod Vas ili drugih - na primjer, pojačan spolni nagon